Chemotherapy-Induced Peripheral Neuropathy

Introduction to Chemotherapy-Induced Neuropathy

The American Society of Clinical Oncology notes that chemotherapy can cause peripheral neuropathies, primarily affecting sensitivity, manifesting as numbness, tingling, and pain in a "glove and stocking" distribution, starting distally in fingers and toes, and potentially progressing proximally as the condition worsens 1, 2

Agentes quimioterapéuticos y riesgo de neuropatía

The American Society of Clinical Oncology identifies platinos, taxanos, ixabepilona, and talidomida as highly neurotoxic agents, while bortezomib and vinca alkaloids are less neurotoxic but also cause neuropathy 3, 4
Paclitaxel causes more prominent neuropathy in lower limbs during treatment, whereas oxaliplatin-induced neuropathy is more severe in upper limbs 4, 1

Características clínicas de las neuropatías inducidas por quimioterapia

The American Society of Clinical Oncology states that paclitaxel-induced neuropathy tends to improve in the months following treatment completion 5, 1
Oxaliplatin-induced neuropathy worsens during 2-3 months after therapy completion (a "coasting" phenomenon) and then begins to improve 5, 1

Diagnóstico

The American Society of Clinical Oncology recommends that the diagnosis of chemotherapy-induced peripheral neuropathy is generally made through clinical history 5, 1

Impacto en la calidad de vida

The American Society of Clinical Oncology notes that chemotherapy-induced peripheral neuropathy can markedly affect patients' quality of life 5, 1

Prevención y manejo

The American Society of Clinical Oncology states that there are no established agents recommended for the prevention of chemotherapy-induced peripheral neuropathy in patients undergoing neurotoxic chemotherapy 6, 2, 7
Duloxetine is the only agent with adequate evidence to support its use in patients with established painful chemotherapy-induced peripheral neuropathy, although the benefit is limited 6, 2, 3

Vitamin B12 for Chemotherapy-Induced Peripheral Neuropathy

Evidence on B12 for CIPN

A randomized, open-label, crossover study comparing duloxetine to vitamin B12 found that duloxetine was significantly more effective than vitamin B12 in reducing numbness (p=0.03) and pain (p=0.04) associated with CIPN 8
A placebo-controlled trial evaluating an oral vitamin B complex in patients receiving neurotoxic chemotherapy found no significant reduction in the incidence of CIPN compared to placebo (p=0.73) 9
In a direct comparison between duloxetine and vitamin B12, duloxetine showed superior efficacy for both numbness and pain associated with CIPN 8
When comparing duloxetine to pregabalin in a 2020 trial, pregabalin showed greater improvement in visual analog scores (93% vs 38%, p<0.001) 8

Current Recommended Approaches for CIPN

Acupuncture combined with methylcobalamin (B12) showed better pain reduction than methylcobalamin alone, suggesting B12 might have a role as an adjunctive therapy rather than monotherapy 10
The American Society of Clinical Oncology does not have a specific guideline for vitamin B12 in CIPN, however duloxetine is recommended as a first-line treatment for patients with established painful CIPN 8

Treatment Algorithm for CIPN

First-line: Duloxetine (20mg/day orally for first week, then 40mg/day) 10, 8
Alternative: Pregabalin (if duloxetine is not tolerated or ineffective) 8
Consider acupuncture as an adjunctive non-pharmacological approach 10

Prevention of Chemotherapy-Induced Polyneuropathy

Risk Assessment Before Chemotherapy

The American Society of Clinical Oncology (ASCO) recommends assessing the following risk factors before starting neurotoxic chemotherapy: pre-existing neuropathy, diabetes mellitus, and family history of hereditary neuropathies 11, 12, 13
The cumulative dose of neurotoxic substances, such as platinum compounds, taxanes, vinca alkaloids, bortezomib, and thalidomide, should be considered when evaluating the risk of chemotherapy-induced polyneuropathy (CIPN) 11

Substances Not Recommended for Prevention

The ASCO guidelines strongly recommend against using the following substances for CIPN prevention: acetyl-L-carnitine, amifostin, amitriptylin, calcium/magnesium, cannabinoids, gabapentin/pregabalin, glutathione, and metformin 11, 12, 13
Acetyl-L-carnitine is not recommended due to strong evidence showing that its harm outweighs its benefits 11, 12, 13

Interventions with Insufficient Evidence

The following interventions have insufficient evidence to support their use outside of clinical trials: acupuncture, cryotherapy, compression therapy, exercise therapy, and ganglioside monosialic acid (GM-1) 11, 12, 14
Cryotherapy has shown mixed results with high discontinuation rates due to patient complaints 14

Practical Approach During Chemotherapy

If intolerable neuropathy or functional nerve impairment occurs, consider dose reduction of the neurotoxic substance, switching to non-neurotoxic alternatives, or discontinuing chemotherapy 11, 12, 14

Important Pitfalls

Avoid prophylactic use of gabapentin/pregabalin, as they are ineffective in preventing CIPN 11, 12, 13
Avoid using acetyl-L-carnitine, as it may worsen neuropathy 11, 12, 13
Do not omit risk assessment before therapy, as this may fail to identify high-risk patients 11, 12

Treatment of Established CIPN

Duloxetine is the only medication with sufficient evidence for the treatment of established CIPN 11, 12, 13

Management of Coasting Phenomenon in Chemotherapy-Induced Peripheral Neuropathy

Pharmacological Management

The American Society of Clinical Oncology recommends duloxetine as the only evidence-based pharmacological option for painful CIPN during the coasting period, with intermediate evidence quality and moderate strength of recommendation 15, 16, 17
Duloxetine should be started at 20 mg daily for the first week, then increased to 40 mg daily, with benefits equal to harms according to ASCO guidelines 15

Non-Pharmacological Supportive Measures

Exercise therapy, such as home-based muscle strengthening and balancing exercises, may provide benefit during the coasting period, with significant reduction in neuropathic pain scores (p < 0.0001) 15
Exercise is feasible, safe, and promising, though larger definitive studies are needed 15, 17

Quality of Life Considerations

The American Society of Clinical Oncology notes that CIPN can markedly affect quality of life and may persist as a debilitating problem for years in some patients 15
The benefits of completing full oxaliplatin dosing should be weighed against the risk of developing long-term, irreversible CIPN, particularly in palliative versus curative treatment settings 16, 17

Chemotherapy-Induced Peripheral Neuropathy Management

Exercise and Physical Rehabilitation

The American Society of Clinical Oncology (ASCO) suggests that exercise therapy, including home-based, moderate-intensity walking and resistance programs, can significantly reduce symptom severity in patients with chemotherapy-induced peripheral neuropathy (CIPN) 18, 19.
Supervised exercise programs, including endurance, resistance, and balance training, have demonstrated that neuropathic symptoms remain stable in intervention groups while significantly worsening in control groups 18.
The correlation between CIPN improvement and balance function changes suggests a mechanistic pathway worthy of deeper investigation 19.

Pharmacological Interventions

The American Society of Clinical Oncology (ASCO) currently states that duloxetine is the only evidence-based pharmacological treatment for CIPN, but notes that larger definitive studies are needed to confirm efficacy and clarify risks 20, 21.
Acetyl-L-carnitine should NOT be used for either prevention or treatment of CIPN, as it may worsen neurotoxicity with harms outweighing benefits 20, 21.

Risk Stratification and Prevention

Pre-treatment risk assessment for diabetes, pre-existing neuropathy, and hereditary neuropathies is recommended but underutilized in clinical practice, according to the American Society of Clinical Oncology (ASCO) 20.